王小波 发表于 2012-8-13 10:48:15

求海外医药研发专家

<DIV>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: 仿宋_GB2312; mso-bidi-font-size: 10.5pt">项目概况〈包括主要工艺流程<SPAN lang=EN-US>,</SPAN>原材料<SPAN lang=EN-US>,</SPAN>人数及技术人员,有关主要设备<SPAN lang=EN-US>,</SPAN>型号、制造国及厂家等情况〉<SPAN lang=EN-US></SPAN></SPAN></P>
<P style="TEXT-INDENT: 21pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: 2.0" class=MsoNormal><SPAN style="FONT-FAMILY: 仿宋_GB2312; mso-bidi-font-size: 10.5pt; mso-hansi-font-family: 宋体">注射用缓控释微球属于国家十二五重点支持项目,项目总投资预计<SPAN lang=EN-US>4000</SPAN>万元,属于化药仿制药,该项目已完成处方筛选、工艺研究、质量研究及稳定性研究,完成药理毒理研究,计划于<SPAN lang=EN-US>2013</SPAN>年底进行生产申报。<SPAN lang=EN-US></SPAN></SPAN></P>
<P style="TEXT-INDENT: 21pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: 2.0" class=MsoNormal><SPAN style="FONT-FAMILY: 仿宋_GB2312; mso-bidi-font-size: 10.5pt; mso-hansi-font-family: 宋体">公司已经成功搭建了注射用缓释微球研发生产平台,重新扩建和进行了厂房改造,自行设计订购了一整套适合于微球生产的符合<SPAN lang=EN-US>GMP</SPAN>要求的设备。所有的微球生产及相关步骤均在相对封闭的反应体系内完成,保证了微球生产的全程无菌控制,这套生产线在国内微球生产中还未见有相关报道,属于首创。并且微球生产车间全部按照<SPAN lang=EN-US>GMP</SPAN>的要求设计施工,符合<SPAN lang=EN-US>GMP</SPAN>的生产要求,为微球生产的全程无菌控制提供支持,保证了产品的用药安全性。<SPAN lang=EN-US></SPAN></SPAN></P>
<P style="TEXT-INDENT: 21pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: 2.0" class=MsoNormal><SPAN style="FONT-FAMILY: 仿宋_GB2312; mso-bidi-font-size: 10.5pt; mso-hansi-font-family: 宋体">在微球的质量检定方面,采用目前先进的检测设备,对产品质量进行全面的控制,使生产出来的产品具有质量可控性。检测配套设备包括气相色谱仪、液相色谱仪(其中包括荧光检测器、紫外检测器和示差折光检测器等配套设施)、粒度分析仪。检测设备足以满足自制产品的质量检测要求,使产品真正达到质量可控。</SPAN><SPAN style="FONT-FAMILY: 仿宋_GB2312; mso-bidi-font-size: 10.5pt" lang=EN-US></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: 仿宋_GB2312; mso-bidi-font-size: 10.5pt" lang=EN-US>&nbsp;</SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: 仿宋_GB2312; mso-bidi-font-size: 10.5pt">需要外国专家解决的主要问题<SPAN lang=EN-US>: </SPAN></SPAN></P>
<P style="TEXT-INDENT: 21pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: 2.0" class=MsoNormal><SPAN style="FONT-FAMILY: 仿宋_GB2312; mso-bidi-font-size: 10.5pt; mso-hansi-font-family: 宋体">该项目按照化药仿制药进行申报注册,关键在于如何确保产品与参比制剂一致。<SPAN lang=EN-US></SPAN></SPAN></P>
<P style="TEXT-INDENT: -21pt; MARGIN: 0cm 0cm 0pt 21pt; mso-list: l0 level1 lfo1; tab-stops: list 21.0pt" class=MsoNormal><SPAN style="FONT-FAMILY: 仿宋_GB2312; mso-bidi-font-size: 10.5pt; mso-hansi-font-family: 宋体; mso-bidi-font-family: 仿宋_GB2312" lang=EN-US><SPAN style="mso-list: Ignore">1.<SPAN style="FONT: 7pt 'Times New Roman'">&nbsp;&nbsp; </SPAN></SPAN></SPAN><SPAN style="FONT-FAMILY: 仿宋_GB2312; mso-bidi-font-size: 10.5pt; mso-hansi-font-family: 宋体">处方一致性的确认:在进行处方筛选时,应如何进行处方设计及筛选?如何对<SPAN lang=EN-US>PLGA</SPAN>辅料进行筛选确认的?如何评价产品与参比制剂是否一致?<SPAN lang=EN-US></SPAN></SPAN></P>
<P style="TEXT-INDENT: -21pt; MARGIN: 0cm 0cm 0pt 21pt; mso-list: l0 level1 lfo1; tab-stops: list 21.0pt" class=MsoNormal><SPAN style="FONT-FAMILY: 仿宋_GB2312; mso-bidi-font-size: 10.5pt; mso-hansi-font-family: 宋体; mso-bidi-font-family: 仿宋_GB2312" lang=EN-US><SPAN style="mso-list: Ignore">2.<SPAN style="FONT: 7pt 'Times New Roman'">&nbsp;&nbsp; </SPAN></SPAN></SPAN><SPAN style="FONT-FAMILY: 仿宋_GB2312; mso-bidi-font-size: 10.5pt">质量一致性</SPAN><SPAN style="FONT-FAMILY: 仿宋_GB2312; mso-bidi-font-size: 10.5pt; mso-hansi-font-family: 宋体">的确认:在进行质量研究时,应用何种体外溶出度方法进行质量控制?如何建立产品的体外溶出度标准?如何判断产品与参比制剂体外溶出度一致?需要对产品与参比制剂杂质谱的一致性进行考察,通过何种方法进行评价,判断二者杂质谱一致的指标是什么?对不一致的杂质应如何控制?如何对产品进行质量控制,<SPAN lang=EN-US></SPAN></SPAN></P>
<P style="TEXT-INDENT: -21pt; MARGIN: 0cm 0cm 0pt 21pt; mso-list: l0 level1 lfo1; tab-stops: list 21.0pt" class=MsoNormal><SPAN style="FONT-FAMILY: 仿宋_GB2312; mso-bidi-font-size: 10.5pt; mso-hansi-font-family: 宋体; mso-bidi-font-family: 仿宋_GB2312" lang=EN-US><SPAN style="mso-list: Ignore">3.<SPAN style="FONT: 7pt 'Times New Roman'">&nbsp;&nbsp; </SPAN></SPAN></SPAN><SPAN style="FONT-FAMILY: 仿宋_GB2312; mso-bidi-font-size: 10.5pt">有效一致性</SPAN><SPAN style="FONT-FAMILY: 仿宋_GB2312; mso-bidi-font-size: 10.5pt; mso-hansi-font-family: 宋体">的确认:注射用缓控释制剂不同于口服缓控释制剂或其他注射制剂,该类产品在进行仿制药申报时,其生物等效性是如何控制的?产品的质量对比研究应如何进行?<SPAN lang=EN-US></SPAN></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: 仿宋_GB2312; mso-bidi-font-size: 10.5pt" lang=EN-US>&nbsp;</SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: 仿宋_GB2312; mso-bidi-font-size: 10.5pt">需达到的指标<SPAN lang=EN-US>(</SPAN>请填写技术数据或对产品改进的数据要求〉<SPAN lang=EN-US>:</SPAN></SPAN></P>
<P style="TEXT-ALIGN: left; TEXT-INDENT: 15.75pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: 1.5; mso-layout-grid-align: none" class=MsoNormal align=left><SPAN style="FONT-FAMILY: 仿宋_GB2312; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-bidi-font-family: 宋体" lang=EN-US><SPAN style="mso-spacerun: yes">&nbsp;</SPAN></SPAN><SPAN style="FONT-FAMILY: 仿宋_GB2312; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-bidi-font-family: 宋体">达到的目标:能筛选出一个收率较高,工艺稳定,质量可控的微球产品,并能够成功申报上市;<SPAN lang=EN-US></SPAN></SPAN></P>
<P style="TEXT-ALIGN: left; MARGIN: 0cm 0cm 0pt; mso-layout-grid-align: none" class=MsoNormal align=left><SPAN style="FONT-FAMILY: 仿宋_GB2312; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-bidi-font-family: 宋体">具体的技术指标及参数:<SPAN lang=EN-US></SPAN></SPAN></P>
<P style="TEXT-ALIGN: left; MARGIN: 0cm 0cm 0pt; mso-layout-grid-align: none" class=MsoNormal align=left><SPAN style="FONT-FAMILY: 仿宋_GB2312; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-bidi-font-family: 宋体">(<SPAN lang=EN-US>1</SPAN>)制备工艺控制:<SPAN lang=EN-US></SPAN></SPAN></P>
<P style="TEXT-ALIGN: left; TEXT-INDENT: 5.25pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: .5; mso-layout-grid-align: none" class=MsoNormal align=left><SPAN style="FONT-FAMILY: 仿宋_GB2312; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-bidi-font-family: 宋体">①确定微球的制备工艺;<SPAN lang=EN-US></SPAN></SPAN></P>
<P style="TEXT-ALIGN: left; TEXT-INDENT: 5.25pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: .5; mso-layout-grid-align: none" class=MsoNormal align=left><SPAN style="FONT-FAMILY: 仿宋_GB2312; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-bidi-font-family: 宋体">②微球收率在<SPAN lang=EN-US>70%</SPAN>以上;<SPAN lang=EN-US></SPAN></SPAN></P>
<P style="TEXT-ALIGN: left; TEXT-INDENT: 5.25pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: .5; mso-layout-grid-align: none" class=MsoNormal align=left><SPAN style="FONT-FAMILY: 仿宋_GB2312; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-bidi-font-family: 宋体">③结合生产工艺对生产设备及生产车间进行设计,并达到<SPAN lang=EN-US>GMP </SPAN>要求;<SPAN lang=EN-US></SPAN></SPAN></P>
<P style="TEXT-ALIGN: left; MARGIN: 0cm 0cm 0pt; mso-layout-grid-align: none" class=MsoNormal align=left><SPAN style="FONT-FAMILY: 仿宋_GB2312; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-bidi-font-family: 宋体">(<SPAN lang=EN-US>2</SPAN>)微球或药棒质量控制:<SPAN lang=EN-US></SPAN></SPAN></P>
<P style="TEXT-ALIGN: left; TEXT-INDENT: 5.25pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: .5; mso-layout-grid-align: none" class=MsoNormal align=left><SPAN style="FONT-FAMILY: 仿宋_GB2312; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-bidi-font-family: 宋体">①微球产品纯度应不低于<SPAN lang=EN-US>96%</SPAN>;<SPAN lang=EN-US></SPAN></SPAN></P>
<P style="TEXT-ALIGN: left; TEXT-INDENT: 5.25pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: .5; mso-layout-grid-align: none" class=MsoNormal align=left><SPAN style="FONT-FAMILY: 仿宋_GB2312; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-bidi-font-family: 宋体">②对微球产品中的其他相关产物质和杂质进行鉴定。<SPAN lang=EN-US></SPAN></SPAN></P>
<P style="TEXT-ALIGN: left; MARGIN: 0cm 0cm 0pt; mso-layout-grid-align: none" class=MsoNormal align=left><SPAN style="FONT-FAMILY: 仿宋_GB2312; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-bidi-font-family: 宋体">(<SPAN lang=EN-US>3</SPAN>)批量:<SPAN lang=EN-US>2000</SPAN>支到<SPAN lang=EN-US>20000</SPAN>万支每批<SPAN lang=EN-US></SPAN></SPAN></P>
<P style="TEXT-ALIGN: left; TEXT-INDENT: 21pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: 2.0; mso-layout-grid-align: none" class=MsoNormal align=left><SPAN style="FONT-FAMILY: 仿宋_GB2312; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-bidi-font-family: 宋体">最终获得微球产品的新药证书。<SPAN lang=EN-US></SPAN></SPAN></P></DIV>
页: [1]
查看完整版本: 求海外医药研发专家